Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for

Sudipto Mukherjee1, George A Pantelopulos1, Vincent A Voelz1

  • 1Department of Chemistry, Temple University, Philadelphia, PA, USA.

Scientific Reports
|August 20, 2016
PubMed

Insights

Markov State Models reveal how the MDM2 protein

Area of Science:

  • Computational Biology
  • Structural Biology
  • Drug Discovery

Background:

  • MDM2 is a key negative regulator of p53 tumor suppressor activity.
  • MDM2 is a significant target for developing novel cancer therapeutics.
  • The N-terminal lid region of MDM2 influences p53 binding by competing for the p53 binding cleft.

Purpose of the Study:

  • To elucidate the dynamic conformational changes of apo-MDM2 (MDM2 without p53).
  • To understand the folding and binding mechanisms of the MDM2 N-terminal region.
  • To assess the utility of MDM2 dynamics in computational drug design against cancer.

Main Methods:

  • Construction of Markov State Models (MSMs) from extensive unbiased molecular dynamics simulations of apo-MDM2.
  • Analysis of N-terminal lid region dynamics and its conformational states.
  • Fixed-anchor docking studies utilizing simulated receptor ensembles against known ligands.

Main Results:

  • MSMs revealed a two-state folding and binding mechanism for the MDM2 N-terminal region.
  • Identified holo-like MDM2 conformations suitable for computational docking, even from closed-cleft starting structures.
  • Simulated ensembles achieved docking success rates comparable to cross-docking studies using crystal structures.

Conclusions:

  • MDM2 + MSM approaches effectively sample binding-competent receptor conformations.
  • These methods are suitable for computational peptidomimetic design targeting MDM2.
  • Inclusion of disordered regions is crucial for accurately capturing receptor dynamics relevant to drug design.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.4K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.6K
Ligand Binding Sites02:40

Ligand Binding Sites

9.0K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.5K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.3K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.8K